Fibroblast growth factor receptor 4 polymorphism is associated with liver cirrhosis in hepatocarcinoma.

doi:10.1371/journal.pone.0122961

中山醫學大學機構典藏 CSMUIR > 醫學院 > 醫學系 > 期刊論文 > Item 310902500/17670

Please use this identifier to cite or link to this item: https://ir.csmu.edu.tw:8080/ir/handle/310902500/17670

Title:	Fibroblast growth factor receptor 4 polymorphism is associated with liver cirrhosis in hepatocarcinoma.
Authors:	MJ, Sheu MJ, Hsieh WL, Chiang SF, Yang HL, Lee LM, Lee CB, Yeh
Contributors:	中山醫學大學醫學系
Date:	2015-04
Issue Date:	2017-04-05T08:53:35Z (UTC)
Publisher:	PLoS One.
ISSN:	2414-7745
Abstract:	BACKGROUND: Fibroblast growth factor receptor 4 (FGFR4) polymorphisms are positively correlated with tumor progression in numerous malignant tumors. However, the association between FGFR4 genetic variants and the risk of hepatocellular carcinoma (HCC) has not yet been determined. In this study, we investigated the potential associations of FGFR4 single nucleotide polymorphisms (SNPs) with HCC susceptibility and its clinicopathological characteristics. METHODOLOGY/PRINCIPAL FINDINGS: Four SNPs in FGFR4 (rs1966265, rs351855, rs2011077, and rs7708357) were analyzed among 884 participants, including 595 controls and 289 patients with HCC. The samples were further analyzed to clarify the associations between these gene polymorphisms and the risk of HCC, and the impact of these SNPs on the susceptibility and clinicopathological characteristics of HCC. After adjusting for other covariants, HCC patients who carrying at least one A genotype (GA and AA) at rs351855 were observed to have a higher risk of liver cirrhosis compared with those carrying the wild-type genotype (GG) (OR: 2.113, 95% CI: 1.188-3.831). Moreover, the patients with at least one A genotype were particularly showed a high level of alpha-fetoprotein (AFP). CONCLUSIONS: Our findings suggest that genetic polymorphism in FGFR4 rs351855 may be associated with the risk of HCC coupled with liver cirrhosis and may markedly increase the AFP level in Taiwanese patients with HCC. In addition, this is the first study that evaluated the risk factors associated with FGFR4 polymorphism variants in Taiwanese patients with HCC.
URI:	http://dx.doi.org/10.1371/journal.pone.0122961 https://ir.csmu.edu.tw:8080/ir/handle/310902500/17670
Relation:	PLoS One. 2015 Apr 10;10(4):e0122961.
Appears in Collections:	[醫學系] 期刊論文

Files in This Item:

File	Description	Size	Format
index.html		0Kb	HTML	261	View/Open

View Licence

Loading...